Biospecifics Tech Cp (BSTC) 40.96 $BSTC BioSpecifics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biospecifics Tech Cp (BSTC) 40.96 $BSTC

BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
PR Newswire - Mon Jun 13, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
PR Newswire - Tue May 31, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum." The data show that highly purified CCH can reduce the stiffness of human uterine fibroids ex-vivo and potentially decrease their size.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.
BSTC: 40.96 (+0.46)

New Strong Sell Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:48AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AIXG: 6.36 (+0.10), BSTC: 40.96 (+0.46), AZZ: 62.93 (+0.85), ASB: 18.48 (-0.12), AHT: 5.91 (-0.05)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 40.96 (+0.46), ARQL: 1.68 (+0.02), APRI: 0.31 (unch), RPRX: 1.93 (-0.19)

Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 40.96 (+0.46), JAZZ: 150.69 (-0.28), ARQL: 1.68 (+0.02), APRI: 0.31 (unch)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.40 (-0.15), ENDP: 16.87 (-0.49), BSTC: 40.96 (+0.46), ARQL: 1.68 (+0.02)

ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 40.96 (+0.46), INCY: 90.17 (-0.04), ARQL: 1.68 (+0.02), ARIA: 9.67 (+0.16)

BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
PR Newswire - Tue May 03, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Tuesday, May 10, 2016 to report its first quarter 2016 financial results and to provide a corporate update.
BSTC: 40.96 (+0.46)

Why BioSpecifics Technologies (BSTC) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:33AM CDT
BioSpecifics Technologies (BSTC) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 06, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:40 a.m. ET in New York, NY.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 14, 6:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Present at the 28th Annual ROTH Conference
PR Newswire - Tue Mar 08, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 12:30 p.m. PT in Dana Point, CA.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Report Fourth Quarter and Full Year 2015 Financial Results on Monday, March 14, 2016
PR Newswire - Mon Mar 07, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to report its fourth quarter and full year 2015 financial results and to provide a corporate update.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Present at the Noble Financial Capital Markets' NobleCon12
PR Newswire - Tue Jan 12, 4:00PM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Noble Financial Capital Markets' NobleCon12 on Tuesday, January 19, 2016 at 9:30 a.m. ET in Sandpiper Bay, FL.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. to Present at the Stifel 2015 Healthcare Conference
PR Newswire - Mon Nov 16, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Stifel 2015 Healthcare Conference.
BSTC: 40.96 (+0.46)

BioSpecifics Technologies Corp. Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 6:30AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2015 and provided a corporate update.
BSTC: 40.96 (+0.46)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 122

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 491

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 307

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 75

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 58

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 14

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading

Top 5 Most Recently Viewed Articles

Genius Group Takes Center Stage at Major Investor Events

Updated Category News Views 214

Genius Group Highlights Major Sponsorships in 2025 Genius Group Limited (NYSE: GNS), an AI-driven education enterprise that prioritizes Bitcoin, has announced its participation in two pivotal investor summits. These events provide a significant platform for the company to engage with institutional investors and emphasize its innovative approach to digital assets. Engaging...

Continue Reading
Miami International Holdings Celebrates Robust Q3 Growth

Updated Category News Views 172

Miami International Holdings Reports Strong Financial Performance Miami International Holdings, Inc. (MIH) (NYSE: MIAX) has recently announced impressive financial outcomes for its third quarter, highlighting a remarkable growth trend. The financial data unveiled reflects the organization's ability to thrive in a highly competitive landscape. With a net revenue increase...

Continue Reading
Market Insights: Momo Crowd and GM's Tariff Burdens

Updated Category News Views 382

Understanding Momo Crowd Dynamics in Today's Market The stock market consistently reflects a myriad of influences, one of which is the behavior of retail investors, commonly referred to as the 'momo crowd.' Recent analyses indicate that the actions of these investors can significantly shape market trends, especially during times of heightened volatility. The Cautionary...

Continue Reading
Cathie Wood Praises Shopify: The Future of AI in Retail Awaits

Updated Category News Views 129

Cathie Wood's Enthusiastic Endorsement of Shopify ARK Invest, led by the visionary Cathie Wood, has recently expressed considerable confidence in Shopify Inc. SHOP. This faith stems from the company's forward-thinking approach toward artificial intelligence, particularly their dedicated focus on what they call 'agentic AI'. As the retail landscape evolves, many investors...

Continue Reading
Liftoff IPO: What’s the Real Play Behind the Curtain?

Updated Category News Views 244

Liftoff Mobile's been in the game since day one—on February 17, 2026, they dropped a bombshell, submitting their draft registration statement for an initial public offering (IPO) with the SEC. But hold your horses: nobody knows how many shares will float or what price range they’re angling for. That vagueness? Classic Wall Street move to stir up speculation while...

Continue Reading